<DOC>
	<DOCNO>NCT00700531</DOCNO>
	<brief_summary>Hypothesis : Free light chain removal haemodialysis increase rate renal recovery patient cast nephropathy , severe renal failure de novo multiple myeloma . This study randomise patient multiple myeloma severe renal failure treatment remove free light chain haemodialysis .</brief_summary>
	<brief_title>European Trial Free Light Chain Removal Extended Haemodialysis Cast Nephropathy</brief_title>
	<detailed_description>The EUropean trial free LIght chain removal exTEnded haemodialysis cast nephropathy ( EuLITE ) trial prospective , randomise , multicentre , open label clinical trial investigate clinical benefit FLC removal haemodialysis patient cast nephropathy , dialysis dependent renal failure de novo multiple myeloma . Recruitment commence May 2008 , total 90 patient recruit . Participants randomise , centrally , upon enrolment , either trial chemotherapy FLC removal haemodialysis trial chemotherapy standard high flux haemodialysis . Trial chemotherapy modify PAD regime , consist bortezomib , doxorubicin dexamethasone . FLC removal haemodialysis undertaken use two Gambro HCO 1100 dialysers series , intensive treatment schedule . The primary outcome study independence dialysis 3 month . Secondary outcome : duration dialysis , reduction serum FLC concentration ; myeloma response survival .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Age &gt; = 18 year Dialysis dependent acute renal failure ( eGFR &lt; 15ml/min/1.73m2 ) Fulfils diagnostic criterion diagnosis symptomatic de novo multiple myeloma1 Abnormal serum FLC ratio sFLC concentration &gt; 500 mg/L Myeloma kidney demonstrate renal biopsy ( cast nephropathy ) Ability give inform consent partake study Commencement study within 10 day present enrol unit Age &lt; 18 year Known advance chronic renal failure ( CKD stage IV 45 ; eGFR &lt; 30mls/min/1.73m2 ) evidence significant chronic damage renal biopsy Amyloidosis light chain deposition disease renal biopsy Previous treatment multiple myeloma chemotherapy Haemodynamic instability precludes unsupported dialysis renal replacement therapy Significant cardiac disease ( myocardial infarction last 6 month ; unstable angina ; NYHA class III IV heart failure ; clinically significant pericardial disease ; cardiac amyloidosis ) Advanced disease significant comorbidity : poor short term prognosis , necessitate palliation active disease specific treatment . Inability give informed consent History allergic reaction attributable compound contain boron mannitol History Peripheral neuropathy neuropathic pain ( grade 2 high define NCI CTCAE version 3 ) Clinically significant liver dysfunction ( bilirubin &gt; 1.8mg/dl ( 30Âµmol/L ) ) Known HIV infection Active uncontrolled infection Pregnant lactate woman Inability give inform consent Premenopausal female patient childbearing potential : positive pregnancy test unwilling use effective contraception study Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Cast nephropathy</keyword>
	<keyword>Kidney failure</keyword>
</DOC>